TORC News and Press, resTORbio Inc.

Adicet Bio completes its previously announced merger with resTORbio (NASDAQ: TORC ) and the new combined company will operate under the name 'Adicet Bio, Inc.'. More news on: resTORbio, Inc., Merger & acquisition news, Read more ...

- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on  The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...

MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...

resTORbio (NASDAQ: TORC ) : Q2 GAAP EPS of -$0.15 beats by $0.10 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...

TrialSpark, a tech-enabled drug development partner for speed,quality and innovation of clinical trials, partnered with resTORbio (NASDAQ: TORC )   +7.14%  PM, who has received  an NIA grant to investigate RTB-101 against COVID-19 outside the hospital in a community...

NEW YORK , July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a collaboration with resTORbio, Inc. (Nasdaq: TORC). resTORbio is a clinical-stage biotechnology ...

Eastman Kodak (NYSE: KODK ) +190% . More news on: Eastman Kodak Company, Spectrum Pharmaceuticals, Inc., Soligenix, Inc., Stocks on the move, , Read more ...

The National Institute on Aging has awarded an undisclosed amount of money to resTORbio (NASDAQ: TORC ) to fund a 60-subject randomized, double-blind, placebo-controlled pilot study evaluating oral small molecule RTB101 for COVID-19 post-exposure prophylaxis in adults at least 65 years o...

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled pilot study of RTB101, an investigational orally-administered potent small molecule inhibi...